Literature DB >> 16763854

Focal cortical dysplasia: pathophysiological approach.

Akira Hodozuka1, Hiroshige Tsuda, Kiyotaka Hashizume, Tatsuya Tanaka.   

Abstract

OVERVIEW: Clinical and experimental studies on focal cortical dysplasia (FCD) were carried out.
MATERIALS AND METHODS: For the experimental study, an experimental FCD model of rats was developed. Twenty Wistar rats at 0-2 days after birth were used for the study. Kainic acid (KA) solution was injected stereotaxically into medial and lateral sites of the sensori-motor cortex. Bipolar electrodes were inserted in five rats. Their behavior and electroencephalogram (EEG) were recorded using a digital-video-EEG monitoring system. After observation periods of 1, 2, and 6 months, rats were perfused for pathological study. FCD was observed adjacent to the site of KA injection in all rats more than 1 month after the injection. RESULTS AND DISCUSSIONS: EEG recording demonstrated focal spike discharges in and around the site of injection. However, clinical seizure was not observed. Pathological studies showed decrease in GABA-A receptors and increase in GABA-B receptors not only in the lesion but also in perilesional areas. Fifteen surgical cases of FCD with intractable epilepsy were subjected to the clinical study. Neuro-imaging studies including high-resolution magnetic resonance imaging and single-photon emission computed tomography were performed. Conventional EEG studies demonstrated focal EEG abnormalities with epileptic phenomena. At surgery, intraoperative electrocorticography (ECoG) was performed to localize epileptic foci under neuroleptoanalgesia. Thirteen patients showed epileptiform discharges on preresection ECoG. All foci in non-eloquent areas were resected. Pathological studies including immunohistochemical staining were performed, and the characteristics of the FCD in relation to EEG findings were analyzed. Patients in whom total lesionectomy with complete focus resection was performed had favorable postoperative courses. Nine patients (64.3%) have been seizure-free with reduced medication, and significant improvement was achieved in two patients (14.3%). Electrophysiological examination revealed epileptogenecity not only in the lesions but also in perilesional areas. The immunohistochemical studies showed a decrease in GABA-A receptors and an increase in GABA-B receptors in both the lesions and perilesional areas, but N-methyl-D: -aspartate receptors were almost negative in both areas. Glutamate R1 was decreased in both areas, but glutamate R2 was increased in both areas. These findings support the results of a electrophysiological study.
CONCLUSIONS: In conclusion, not only the epileptic property of experimental focal cortical dysplasia but also perilesional epileptogenesis was demonstrated. These findings supported the results of surgery for patients with focal cortical dysplasia. In cases of FCD, total removal of the lesion and resection of the perilesional epileptic focus are needed for a good outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16763854     DOI: 10.1007/s00381-006-0136-1

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  15 in total

Review 1.  Experimental complex partial seizures induced by a microinjection of kainic acid into limbic structures.

Authors:  T Tanaka; S Tanaka; T Fujita; K Takano; H Fukuda; K Sako; Y Yonemasu
Journal:  Prog Neurobiol       Date:  1992       Impact factor: 11.685

2.  Freezing lesions of the developing rat brain: a model for cerebrocortical microgyria.

Authors:  P Humphreys; G D Rosen; D M Press; G F Sherman; A M Galaburda
Journal:  J Neuropathol Exp Neurol       Date:  1991-03       Impact factor: 3.685

3.  Classification issues in malformations caused by abnormalities of cortical development.

Authors:  André Palmini; Hans O Lüders
Journal:  Neurosurg Clin N Am       Date:  2002-01       Impact factor: 2.509

4.  Cortical dysplasia: an immunocytochemical study of three patients.

Authors:  R Spreafico; G Battaglia; P Arcelli; F Andermann; F Dubeau; A Palmini; A Olivier; J G Villemure; D Tampieri; G Avanzini; M Avoli
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

5.  Epileptogenicity correlated with increased N-methyl-D-aspartate receptor subunit NR2A/B in human focal cortical dysplasia.

Authors:  I M Najm; Z Ying; T Babb; A Mohamed; J Hadam; E LaPresto; E Wyllie; P Kotagal; W Bingaman; N Foldvary; H Morris; H O Lüders
Journal:  Epilepsia       Date:  2000-08       Impact factor: 5.864

6.  Disinhibited in vitro neocortical slices containing experimentally induced cortical dysplasia demonstrate hyperexcitability.

Authors:  S N Roper; M A King; L A Abraham; M A Boillot
Journal:  Epilepsy Res       Date:  1997-03       Impact factor: 3.045

7.  Spontaneous secondarily generalized seizures induced by a single microinjection of kainic acid into unilateral amygdala in cats.

Authors:  T Tanaka; M Kaijima; Y Yonemasu; C Cepeda
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1985-11

8.  Expression and cell distribution of group I and group II metabotropic glutamate receptor subtypes in taylor-type focal cortical dysplasia.

Authors:  Eleonora Aronica; Jan A Gorter; Gerard H Jansen; Cees W M van Veelen; Peter C van Rijen; Marja Ramkema; Dirk Troost
Journal:  Epilepsia       Date:  2003-06       Impact factor: 5.864

9.  Distribution of glutamate receptor subunits in experimentally induced cortical malformations.

Authors:  G Hagemann; M M Kluska; C Redecker; H J Luhmann; O W Witte
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

10.  [Jacksonian seizure model induced by a kainic acid microinjection into unilateral sensori-motor cortex].

Authors:  K Yamamoto; T Tanaka; Y Yonemasu
Journal:  No To Shinkei       Date:  1995-05
View more
  1 in total

1.  Contributions of EEG-fMRI to Assessing the Epileptogenicity of Focal Cortical Dysplasia.

Authors:  Francesca Pittau; Lorenzo Ferri; Firas Fahoum; François Dubeau; Jean Gotman
Journal:  Front Comput Neurosci       Date:  2017-02-20       Impact factor: 2.380

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.